×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ARMP – armata pharmaceuticals, inc. (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ARMP
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/2
10:42 am
armp
H.C. Wainwright Reaffirms Buy on Armata Pharmaceuticals, Inc. (ARMP) After FDA Nod [Yahoo! Finance]
Medium
Report
H.C. Wainwright Reaffirms Buy on Armata Pharmaceuticals, Inc. (ARMP) After FDA Nod [Yahoo! Finance]
2/23
07:00 am
armp
Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02
Medium
Report
Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02
1/13
07:21 am
armp
Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated BacteremiaStaphylococcusaureus [Yahoo! Finance]
High
Report
Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated BacteremiaStaphylococcusaureus [Yahoo! Finance]
1/13
07:00 am
armp
Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated BacteremiaStaphylococcusaureus
Medium
Report
Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated BacteremiaStaphylococcusaureus
Date
Time
Symbol
Company Name
Action
%Chg
11/12/2025
04:05 pm
ARMP
armata pharmaceuticals, inc.
MISS
Report
-6.4%
armata pharmaceuticals, inc.
8/12/2025
04:05 pm
ARMP
armata pharmaceuticals, inc.
MISS
Report
1.2%
armata pharmaceuticals, inc.
5/14/2025
04:05 pm
ARMP
armata pharmaceuticals, inc.
BEAT
Report
1.4%
armata pharmaceuticals, inc.
3/20/2025
05:56 pm
ARMP
armata pharmaceuticals, inc.
BEAT
Report
-10.9%
armata pharmaceuticals, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
2/23
07:11 am
armp
Form 8-K Armata Pharmaceuticals, For: Feb 23
Medium
Report
Form 8-K Armata Pharmaceuticals, For: Feb 23
1/26
04:06 pm
armp
Form SCHEDULE 13D/A Armata Pharmaceuticals, Filed by: Innoviva, Inc.
Medium
Report
Form SCHEDULE 13D/A Armata Pharmaceuticals, Filed by: Innoviva, Inc.
1/26
08:01 am
armp
Form 8-K Armata Pharmaceuticals, For: Jan 26
Medium
Report
Form 8-K Armata Pharmaceuticals, For: Jan 26
1/13
07:11 am
armp
Form 8-K Armata Pharmaceuticals, For: Jan 13
High
Report
Form 8-K Armata Pharmaceuticals, For: Jan 13
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
1/28
Armata Pharmaceuticals and Innoviva Announce $25 Million Strategic Investment to Support Advancement of Armata's Bacteriophage Development Programs
70.3%
5/28 Armata Pharmaceuticals Announces Publication of Successful Adjunctive Phage Treatment in Cystic Fibrosis Patient 45.0%
5/9 C3J Therapeutics and AmpliPhi Biosciences Announce Successful Completion of Merger and Formation of Bacteriophage Company Armata Pharmaceuticals, Inc. 16.0%
10/11 Form PRE 14A Armata Pharmaceuticals, For: Dec 10 11.8%
3/18 Armata Pharmaceuticals Announces up to $5 Million Therapeutics Development Award from the Cystic Fibrosis Foundation 10.9%
5/16 Form 3 Armata Pharmaceuticals, For: May 09 Filed by: Varnum Brian 6.3%
1/29 Form 8-K Armata Pharmaceuticals, For: Jan 27 4.5%
6/24 Form 8-K Armata Pharmaceuticals, For: Jun 24 4.3%
1/9 Form S-1/A Armata Pharmaceuticals, 4.3%
3/30 Armata Pharmaceuticals Announces Closing of Second Tranche of $25 Million Securities Purchase Agreement with Innoviva, Inc. 4.1%
5/28 Armata Pharmaceuticals Announces Publication of Successful Adjunctive Phage Treatment in Cystic Fibrosis Patient 45.0%
5/9 C3J Therapeutics and AmpliPhi Biosciences Announce Successful Completion of Merger and Formation of Bacteriophage Company Armata Pharmaceuticals, Inc. 16.0%
10/11 Form PRE 14A Armata Pharmaceuticals, For: Dec 10 11.8%
3/18 Armata Pharmaceuticals Announces up to $5 Million Therapeutics Development Award from the Cystic Fibrosis Foundation 10.9%
5/16 Form 3 Armata Pharmaceuticals, For: May 09 Filed by: Varnum Brian 6.3%
1/29 Form 8-K Armata Pharmaceuticals, For: Jan 27 4.5%
6/24 Form 8-K Armata Pharmaceuticals, For: Jun 24 4.3%
1/9 Form S-1/A Armata Pharmaceuticals, 4.3%
3/30 Armata Pharmaceuticals Announces Closing of Second Tranche of $25 Million Securities Purchase Agreement with Innoviva, Inc. 4.1%
TOP News Decliners
12/20
Form S-1 Armata Pharmaceuticals,
-12.0%
5/20 Form 3 Armata Pharmaceuticals, For: May 09 Filed by: Delta Dental of Wisconsin, Inc. -10.7%
11/12 Armata Pharmaceuticals Announces Third Quarter Results and Provides Corporate and Clinical Update -9.7%
2/21 Form PRE 14A Armata Pharmaceuticals, For: Feb 21 -8.3%
3/30 Form 8-K Armata Pharmaceuticals, For: Mar 26 -6.9%
5/14 Form 8-K Armata Pharmaceuticals, For: May 14 -6.2%
8/14 Q2/2019 6/30/2019 EPS -0.690 ZacksConsensus -0.290 ActVsEst (0.400) - Miss -6.1%
6/3 Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with New Patent Allowances in Europe and Canada -4.8%
7/24 Form 8-K/A Armata Pharmaceuticals, For: May 14 -4.0%
1/13 Form SC 13G/A Armata Pharmaceuticals, Filed by: LILLY ENDOWMENT INC -3.8%
5/20 Form 3 Armata Pharmaceuticals, For: May 09 Filed by: Delta Dental of Wisconsin, Inc. -10.7%
11/12 Armata Pharmaceuticals Announces Third Quarter Results and Provides Corporate and Clinical Update -9.7%
2/21 Form PRE 14A Armata Pharmaceuticals, For: Feb 21 -8.3%
3/30 Form 8-K Armata Pharmaceuticals, For: Mar 26 -6.9%
5/14 Form 8-K Armata Pharmaceuticals, For: May 14 -6.2%
8/14 Q2/2019 6/30/2019 EPS -0.690 ZacksConsensus -0.290 ActVsEst (0.400) - Miss -6.1%
6/3 Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with New Patent Allowances in Europe and Canada -4.8%
7/24 Form 8-K/A Armata Pharmaceuticals, For: May 14 -4.0%
1/13 Form SC 13G/A Armata Pharmaceuticals, Filed by: LILLY ENDOWMENT INC -3.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: